Pediatric thyroid carcinoma: experience in pediatric hospital

João Henrique Cunha Villela¹*, Luiz Roberto Medina dos Santos², Camila Medeiros Machado¹, Fernanda Ceconello¹, Vinicius Muraro Bonatto¹

Abstract

Introduction: Thyroid malignancies are not common in the pediatric patients. The objective of this study was to analyze the thyroid cancer patients operated on in a Pediatric Hospital, between 2012 and 2016, with a description of the diagnosis and therapeutics, including a review of the literature. Methods: A retrospective study by reviewing medical records in a Pediatric Hospital, from 1/1/2012 to 12/31/2016. Results: Ten patients diagnosed with thyroid cancer were analyzed in the five years’ period. The female gender was the most affected with 60% of the cases and 70% of the patients undergone total thyroidectomy associated with some kind of neck dissection. The main histological type was papillary carcinoma in 80% of the cases. All patients are alive and well, in a careful follow-up. Conclusion: The results were in accordance to the epidemiological and clinical features observed in the literature, for this pediatric population. It is important a long follow up for these patients.

Keywords: thyroid neoplasms; carcinoma, papillary; pediatrics; thyroid nodule.

Introduction

Thyroid neoplasms are not common in the pediatric age group¹. In most children, the thyroid nodule is the initial presentation of thyroid cancer¹,². However, the presence of palpable lymph nodes in the cervical region may be the only indication in this age group³. Pediatric thyroid cancer tends to be more aggressive and multifocal, with greater involvement of the cervical lymph nodes and with a greater extracapsular extension of the disease, when compared to the same disease in adults⁴. Ten percent of all thyroid cancers occur in patients younger than 21 years old⁵. In Brazil, the incidence can reach 2% of all pediatric cancers, according to the National Cancer Institute database⁶, and differentiated thyroid carcinoma accounts for about 0.5-3% of all neoplasms in the pediatric population⁷. Also, the thyroid is one of the most common sites of a second primary tumor in children who have received radiation therapy in the neck for the treatment of other neoplasms.

Ultrasonography (US) is the best imaging test for the evaluation of the thyroid nodule, and it may suggest, but not diagnose, the etiology of the nodule⁸. Fine needle aspiration (FNA) is a diagnostic method with a good cost-benefit ratio and it is currently indicated as the first diagnostic option in patients with thyroid and cervical nodules⁹,¹⁰, as well as excellent sensitivity and specificity⁹,¹⁰. Controversies over the aggressiveness of the clinical presentation and the optimal therapeutic approach remain in the scientific community. Current
Thyroid diseases and Tumors

Pediatric thyroid carcinoma: experience in pediatric hospital

recommendations and test systems are based on data generated by studies in adults, which can lead to excessive or incomplete treatments. As in the adults, differentiated thyroid carcinoma is the most common, especially papillary carcinoma. The current treatment recommendation is total thyroidectomy followed by radioiodine therapy, when indicated, based on good response and high disease-free survival rate for the pediatric age group. However, many authors question the aggressiveness of this treatment, given the long-term survival of these patients and the long-term complications of high doses of radioactive iodine. Understanding the differences in biology, clinical course and outcomes in this population is crucial for making therapeutic decisions.

Although children and adolescents with differentiated thyroid carcinoma have more advanced disease at diagnosis, their prognosis is better than in adults. In the pediatric age group, most tumors are derived from follicular cells, such as papillary and follicular carcinomas, with parafollicular cell carcinoma being less frequent.

The occurrence of thyroid carcinoma in early childhood is very rare. In the literature, there are isolated cases of differentiated thyroid carcinoma in neonates and infants less than one-year-old.

Methods

This is a retrospective study that includes all patients aged 0 to 15 years old diagnosed with thyroid cancer after operated by the Head and Neck Surgery Service of Children's Hospital from 01/01/2012 to 12/31/2016.

Patients were identified by searching for all thyroid surgeries performed in the period with conference results of anatomopathological reports of surgical specimens and included in the study those diagnosed with thyroid cancer. The medical records of these patients were separated and reviewed.

The variables analyzed were age, gender, symptomatology, exposure to previous irradiation, family history, surgical indication, FNA of thyroid nodules and cervical lymph nodes when indicated, type of surgery, histological type, pathological staging, adjuvant with radioiodine therapy, serum thyroglobulin dosage, anti-thyroglobulin antibody, calcitonin and CEA when indicated, and eventual relapse.

Results

Ten patients with a diagnosis of thyroid carcinoma treated in this period of 5 years were identified.

The female gender was the most affected by thyroid cancer (six in ten patients). Age at diagnosis ranged from 5 to 13 years old. The presence of thyroid mass and cervical nodules were the most frequent symptoms. There was no record of prior exposure to ionizing radiation for any of these patients.

Nine patients underwent FNA of the thyroid nodule, resulting from the Bethesda classification, where one patient had category Bethesda IV, three had Bethesda V and five had Bethesda VI. Four patients underwent FNA of cervical lymph node, which demonstrated metastatic papillary carcinoma.
In one patient, total prophylactic thyroidectomy was indicated by a familial multiple endocrine neoplasia type IIa (NEM IIa) and having RET +.

Two patients underwent total thyroidectomy, and eight patients underwent total thyroidectomy associated with neck dissection, three of which were to unilateral level VI, two to central compartment and three to central and lateral compartments.

Eight patients had a diagnosis of papillary carcinoma, with three presenting multicentricity, six of them with positive cervical lymph node metastasis (four with prior diagnosis and two after transient suspicion in the perioperative period), a follicular carcinoma and a medullary microcarcinoma in a patient had the prophylactic surgical indication.

Radioiodine therapy was indicated for four patients, all with papillary carcinoma and positive cervical lymph node metastasis, with a dosage varying from 50 to 150 mCi, according to body weight and extent of disease evaluated through pathological staging. In one patient, only whole-body scintigraphy (WBS) was performed for control, without radioiodine therapy. In two patients with positive lymph node metastasis, but with encapsulated tumor, absence of extrathyroidal extension, perineural and angiolymphatic invasion, the choice was made without radioiodine therapy or WBS. Data are in Table 1.

All patients are undergoing rigorous follow-up, in hormonal replacement with levothyroxine, in suppressive doses for thyrotrophic hormone (TSH), and two patients are maintaining anti-thyroglobulin negative antibody and undetectable serum thyroglobulin. Five patients had anti-thyroglobulin-negative antibody and positive serum thyroglobulin level, but low and controlled (0.1 to 1.3 ng/ml).

Table 1. Data from 10 patients diagnosed with thyroid cancer after surgery from 2012 to 2016.

<table>
<thead>
<tr>
<th>Gender</th>
<th>Indication/FNA</th>
<th>Age in Surgery</th>
<th>Surgery</th>
<th>AP</th>
<th>Current Staging</th>
<th>RIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>NEM IIa Ret +</td>
<td>5 years old</td>
<td>TT</td>
<td>Medular MicroCa</td>
<td>pT1aN0Mx</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>IV</td>
<td>13 years old</td>
<td>TT</td>
<td>Follicular CA</td>
<td>pT2NxMx</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>VI</td>
<td>9 years old</td>
<td>TT + Central ND</td>
<td>Papillary CA</td>
<td>pT3N1aMx</td>
<td>50 mCi</td>
</tr>
<tr>
<td>M</td>
<td>V</td>
<td>8 years old</td>
<td>TT + Central ND</td>
<td>Papillary CA</td>
<td>pT1bN0Mx</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>VI</td>
<td>11 years old</td>
<td>TT + right level VI ND</td>
<td>Papillary CA</td>
<td>pT1aN0Mx</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>VI</td>
<td>11 years old</td>
<td>TT + Central ND and Bilateral</td>
<td>Papillary CA</td>
<td>pT3N1bM1pul</td>
<td>150 mCi</td>
</tr>
<tr>
<td>F</td>
<td>V</td>
<td>9 years old</td>
<td>TT + Central ND</td>
<td>Papillary CA</td>
<td>pT2N1aMx</td>
<td>50 mCi</td>
</tr>
<tr>
<td>F</td>
<td>VI</td>
<td>13 years old</td>
<td>TT + right level VI ND</td>
<td>Papillary CA</td>
<td>pT2N1aMx</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>V</td>
<td>13 years old</td>
<td>TT + right level VI ND</td>
<td>Papillary CA</td>
<td>pT2N1aMx</td>
<td>150 mCi</td>
</tr>
<tr>
<td>F</td>
<td>VI</td>
<td>13 years old</td>
<td>TT + Central ND and Bilateral</td>
<td>Papillary CA</td>
<td>pT1bN1bMx</td>
<td>No</td>
</tr>
</tbody>
</table>

CEA= Carcinoembryonic antigen, FNA = fine needle aspiration biopsy, AP = Pathological report, ND = Neck dissection, Ca or CA = Carcinoma, NEM = Multiple endocrine neoplasms; RIT: radioiodine therapy; TT: total thyroidectomy.
The patient with medullary microcarcinoma maintains stable calcitonin and CEA dosages (2.0 pg/ml and 0.4 ng/ml respectively). In two patients, there was a high anti-thyroglobulin antibody (66.3 and 597 IU / ml) and undetectable serum thyroglobulin, with no clinical evidence of relapse, and in a patient, there was anti-thyroglobulin antibody positive and low (0.7 IU/ml) and elevated serum thyroglobulin (300 ng/ml), with pulmonary metastases evidenced by WBS. (Table 2)

All patients are alive, well and in careful follow-up.

**Discussion**

Due to the fact that the thyroid volume is lower in children, early involvement of the thyroid capsule and the surrounding tissue can be observed, and multicentricity also occurs more frequently in this age group, especially in papillary carcinoma\(^{17,18}\). This is important because it favors the indication of total thyroidectomy as a primary surgical approach for these patients. Pediatric patients are more likely to have cervical lymphatic metastasis, as well as distant metastases\(^{19,20}\). In a Mayo Clinic series with 1039 patients with papillary thyroid carcinoma, involvement of cervical lymph nodes was detected in 90% and distant metastases in approximately 7% of children versus 35% of cervical lymph node involvement and 2% of distant metastasis in adults\(^{21}\). The most common site of distant metastasis in children is the lung, with only a few reported cases of bone metastases\(^{15}\) and metastases to the central nervous system\(^{15,22}\). The histological subtype follows a distribution similar to adults: 90-95% of papillary and 5% of follicular carcinomas\(^{23-25}\). Undifferentiated tumors such as insular and anaplastic tumors are extremely rare\(^ {25}\).

An important difference between pediatric and adult thyroid carcinomas is related to the high prevalence of expression of the sodium iodide transporter.

**Table 2.** Data from the 10 patients followed up with the laboratory dosages collected between January and June 2017.

<table>
<thead>
<tr>
<th>Ac Anti-thyroglobulin (UI/ml)</th>
<th>Thyroglobulin (ng/ml)</th>
<th>Calcitonin (pg/ml)</th>
<th>CEA (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>0.1</td>
<td>2</td>
<td>0.4</td>
</tr>
<tr>
<td>Negative</td>
<td>0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>Undetectable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>597</td>
<td>Undetectable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.7</td>
<td>300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>66.3</td>
<td>0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>0.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>Undetectable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CEA = Carcinoembryonic antigen.
Thyroid diseases and Tumors

Pediatric thyroid carcinoma: experience in pediatric hospital

(NIS) in the metastatic focus found in children. The greater expression of NIS in the pediatric population results in a greater capacity to respond to treatment with radioactive iodine and a better prognosis. In young patients, the risk of recurrence increases in those who do not express the NIS protein when compared to those who have it. Thus, the degree of NIS expression correlates with the avidity of radioactive iodine for metastases and lower rates of clinical recurrence.

The prognosis of these tumors in childhood is better and survival seems to be higher, despite having a higher rate of recurrence when compared to adults.

Regardless of the biology of papillary and follicular tumors, the therapeutic approach is very similar for both tumor subtypes. As in adults, the treatment of differentiated thyroid carcinoma is based on the combination of three therapeutic modalities: surgery, hormone replacement with levothyroxine and treatment with radioactive iodine. Surgery may range from lobectomy to total thyroidectomy accompanied by cervical, central and lateral neck dissection. The latest guidelines recommend total thyroidectomy, especially for tumors larger than 1 cm, associated with neck dissection of the central or lateral compartment if lymph node metastases are observed at preoperative imaging or during surgery. The main surgical complications include persistent hypoparathyroidism and lower laryngeal nerve lesion, which can cause a wide spectrum of clinical consequences: from hoarseness to paralysis of both vocal folds, requiring definitive tracheostomy.

The success of radioiodine ablation is significantly lower in patients undergoing less extensive surgery, such as near total thyroidectomy. In most cases, a dose of radioiodine treatment is able to achieve complete ablation. However, the procedure may require repetition, usually 6-12 months after the first procedure. Some variables seem to influence the success of thyroid remnant ablation, and the most important one seems to be the presence of lymph node metastases.

Treatment with hormone replacement therapy with levothyroxine at a suppressive dose reduces the risk of TSH-induced growth or tumor proliferation. In children and adolescents still growing, there are several studies that guarantee the efficacy and safety of this replacement, particularly in relation to the final height, provided they are carefully controlled.

Our study showed that the demand of patients with thyroid cancer was not large in the hospital during the period analyzed. Despite the low prevalence, the diagnosis of this neoplasm should be considered in the investigation of any child, adolescent or young adult with thyroid and cervical nodules, even if asymptomatic.

Although children with thyroid cancer sometimes have locoregional metastases, a high rate of distant metastasis, and relapse, overall survival is very good. Treatment should be based on increased risk of recurrence rather than overall mortality, and lifelong follow-up is necessary because recurrence and death may not occur for decades after diagnosis.

There is still no ideal system for treating thyroid cancer in the pediatric population. These patients are usually grouped under 45 years old, causing
imprecision when including those under 20 years old, who clearly have different clinical presentations and biology when compared to older patients. More studies with this population are needed to develop specific behavior for this age group. All cases of pediatric thyroid cancer should be referred to specialized multidisciplinary teams to minimize possible complications and ensure adequate follow-up.

Conclusion

Uniform management was observed by physical examination of thyroid and/or cervical nodules, followed by evaluation of it through ultrasound and FNA, associated with trimodal treatment, with total thyroidectomy, neck dissection and radiiodine therapy when indicated, associated with suppressive therapy with levothyroxine and follow-up through physical examination, ultrasonography and laboratory control.

References


